Abatacept shortages ‘resolved’

Pharmacies can expect to have improved access to stocks of Bristol-Myers Squibb’s Orencia (abatacept) 125mg/mL ClickJect autoinjector for subcutaneous injection and prefilled syringe products  Following months of supply issues, the company advised the Therapeutic Goods Administration (TGA) last week (30 August 2024) “that the shortages of both abatacept subcutaneous presentations have resolved”.   “Supply has returned